Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Millennium Starts Phase II Prostate Cancer Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Millennium Starts Phase II Prostate Cancer Trial

Takeda Pharmaceutical Co. Ltd. and its wholly-owned subsidiary Millennium, The Takeda Oncology Co., initiated a Phase II trial of TAK-700 in patients with advanced prostate cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda Pharmaceutical Co. Ltd. and its wholly-owned subsidiary Millennium, The Takeda Oncology Co., initiated a Phase II trial of TAK-700 in patients with advanced prostate cancer. TAK-700 is a non-steroidal androgen synthesis inhibitor that has been shown to bind to and inhibit the enzyme 17, 20 lyase1, suppressing the production of androgen.

The open-label, multiple-dose study will examine the safety and efficacy of TAK-700 in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. Primary endpoints of the study are safety and tolerability with secondary measures to include efficacy, pharmacokinetic and pharmacodynamic endpoints.

“Our efforts in the development of drugs for prostate cancer represent a high-priority for Millennium,” said Nancy Simonian, M.D., chief medical officer, Millennium. “TAK-700 is the first drug candidate in our prostate program to advance to Phase II clinical trials. We are pleased to see the progress of this compound, and we are striving to develop drugs that will fulfill the unmet medical need for prostate cancer.”

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics